Wolverine: A Protocol With a Timeline and No Study Behind It

The short version

'Wolverine' is not a molecule. It is a name the research-use community gives to two separate peptides sold together: BPC-157 and TB-500. Because it is a pairing rather than a compound, it has no single structure, no molecular weight and no CAS number of its own.

The reasoning behind combining them is easy to follow. BPC-157 is credited with a signal that grows new blood vessels into damaged tissue ^[4]; TB-500 comes from a protein that helps cells move into a wound and lay down new material ^[10]. Two different jobs, so — the argument goes — they should complement each other.

That argument has never been tested. A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 36 studies, found only one human report among them, found no clinical safety data at all, and did not mention TB-500 or any combination anywhere ^[13]. No study defines a ratio, a dose, an endpoint or a duration for the two given together. The blend's timeline is entirely community-authored.

What it is

The Wolverine blend is a co-formulated pairing of two distinct synthetic peptides, and it is worth stating both precisely because the marketing rarely does.

BPC-157 is a 15-amino-acid pentadecapeptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22, around 1,419.5 daltons, derived from a partial sequence of a Body Protection Compound found in human gastric juice. TB-500 is a synthetic N-acetylated heptapeptide, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, formula C38H68N10O14, around 889.0 daltons, corresponding to residues 17 to 23 — the actin-binding motif — of the 43-residue protein thymosin beta-4, which itself weighs around 4,963 daltons.

It also circulates as the BPC-157/TB-500 blend, the BPC-157 + TB-500 stack, the Wolverine peptide stack and simply BPC157 TB500.

Neither component is approved by the FDA for human use and the blend has no approved therapeutic indication. In 2023 the FDA placed BPC-157 in a category of bulk drug substances identified as not eligible for compounding under section 503A; thymosin beta-4-related peptides were also flagged in the agency's compounding review. Both constituents are prohibited by the World Anti-Doping Agency — BPC-157 under the S0 non-approved-substances category, TB-500 and thymosin beta-4 under the peptide, growth-factor and tissue-repair categories — in and out of competition for the relevant classes. The blend is sold for laboratory research use only.

How it works, in theory

The blend is rationalised as a two-mechanism pairing. BPC-157 is said to supply a local cytoprotective and pro-angiogenic signal through VEGFR2-Akt-eNOS up-regulation, nitric-oxide modulation and growth-hormone-receptor-driven fibroblast and tendocyte proliferation ^[4]. TB-500, through the thymosin beta-4 actin-binding motif, is said to supply an intracellular signal that sequesters monomeric G-actin one-to-one and so regulates the cytoskeletal dynamics behind cell migration, re-epithelialisation and progenitor mobilisation ^[10].

The two are described as acting through complementary but largely non-overlapping pathways, and that non-overlap is the entire basis of the synergy claim.

It is a theoretical extrapolation from each peptide's independently characterised mechanism. No controlled head-to-head or combination study has defined a synergistic dose, ratio or endpoint for the two given together. Nothing in the corpus establishes that two signals aimed at different phases of repair reinforce each other rather than simply running in parallel — or interfere. On a timeline, an angiogenic signal and a cell-migration signal are not obviously simultaneous events, and no study has looked at whether their timing matters.

What the research shows, and what it never measured

There is no research on the blend. What follows is the evidence that bounds it.

The direct negative finding. The 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies — 35 preclinical and one human, a 12-patient retrospective report of intra-articular treatment for knee pain. It found no clinical safety data, concluded that the evidence sits at levels IV to V, the lowest tiers, and made no mention of TB-500 or of any combination or blend ^[13]. A systematic review that screens the field and does not encounter the combination is direct evidence that controlled combination evidence does not exist.

The regulatory and safety anchor. A 2026 Sports Medicine narrative review of approved and unapproved peptide therapies for musculoskeletal conditions, listing both BPC-157 and TB-500/thymosin beta-4, concluded that many unapproved peptides show favourable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, that there is potential for serious harm, and that such compounds operate largely outside regulatory oversight ^[8].

The BPC-157 half, bounded honestly. The 2025 narrative review concluded that despite broad preclinical support, human data for BPC-157 are extremely limited — three pilot studies — that rigorous large-scale trials are lacking, and that it should be treated as investigational given the regulatory controversy and non-regulated availability ^[2].

The two mechanisms, separately. The angiogenic half rests on the VEGFR2 work: up-regulation and internalisation of VEGFR2 with downstream Akt-eNOS activation, increased vessel density and accelerated blood-flow recovery in ischaemic muscle, with the effect blocked by endocytosis inhibition ^[4]. The cytoskeletal half rests on the thymosin beta-4 review: actin binding, cell mobilisation and migration, reduced myofibroblast number and therefore reduced scarring, release by platelets and macrophages after injury, and angiogenesis ^[10].

Set against a time axis, the result is a page-length blank. Onset for the blend: never measured. Duration: never measured. Persistence: never measured. Optimal interval between administrations: never determined. Ratio of one component to the other: never established in any study.

Reported effects, cautions and safety

The following accounts are anecdotal, not clinical evidence. They come from peptide-user forums, athletic-recovery write-ups, wellness-clinic patient anecdotes and published qualitative analysis of online discussion, they are attached to no doses here, and the controlled studies behind the individual peptides were done separately, in animals, not on the blend in people.

Faster recovery from tendon, ligament and muscle injury is very commonly reported, including after sprains, strains, tears and surgery. Reduced inflammation and joint or injury pain is very commonly reported, usually described over the first one to three weeks, with the caveat that relief on that schedule can equally reflect rest, ordinary healing or expectation. Improved gut comfort and digestion is frequently reported and credited specifically to the BPC-157 component. Better sleep and a general sense of recovery is occasionally reported, often attributed by the people reporting it to being in less pain rather than to any direct effect. A mood lift is occasionally reported. On the adverse side, injection-site reactions — stinging, redness, a small lump, soreness — are very commonly reported and usually described as settling within hours to a day or two; fatigue or a flat, sluggish feeling in the first several days is frequently reported and usually pinned on the TB-500 component; head rush, lightheadedness or headache after a dose is frequently reported; mild nausea or dizziness attributed to BPC-157 is occasionally reported; anxiety, insomnia, palpitations or mood swings are occasionally reported, standing in direct contradiction to the people who report a mood lift; and minor hair shedding is rarely reported. One further category deserves its own mention: because these blends are sold through unregulated channels, experienced community members frequently warn that an unexpected reaction may come from contamination, a wrong or truncated sequence, or a vial containing something other than what the label claims, rather than from the peptides at all.

The documented cautions compound rather than average. The blend itself has never been tested, so its combined safety is unknown, and the 2025 systematic review found no human safety data for BPC-157 and no combination data at all ^[13][2]. A theoretical cancer concern applies, because thymosin beta-4 has been linked in laboratory and tumour models to metastasis and tumour blood-vessel growth, and pairing two pro-repair peptides may stack that uncertainty. Both components are unapproved and product identity, purity and the real BPC-157-to-TB-500 ratio are unverifiable in an unregulated vial ^[8]. Both are prohibited in sport, and TB-500 is a recognised doping target with confirmed detection methods. The reassuring human tolerability data people cite were generated with full-length thymosin beta-4 given intravenously, not with the fragment and not with the blend ^[11]. The shared pro-angiogenic mechanism warrants caution wherever new blood-vessel growth is unwanted, such as active cancer or proliferative eye disease ^[4]. Loading-then-maintenance schedules and fixed 10 mg plus 10 mg ratios have no basis in any controlled human trial, and animal work on the thymosin beta-4 side found the highest dose gave no added benefit ^[9]. And long-term human safety is simply not characterised for either peptide or for the pairing ^[2].

Where it sits on the repair timeline

The Wolverine blend is the clearest case on this desk of a timeline that exists entirely in practice and not at all in the literature.

Community protocols are precise: a loading period, then maintenance, then a taper, with fixed vial ratios and week-numbered expectations. The measured record contains none of that. There is no combination study ^[13], no defined ratio, no onset, no duration, and no endpoint. Every interval in circulation was authored by users, not by investigators.

What can be said is bounded and worth saying. The two mechanisms are separately characterised and genuinely different ^[4][10]. Both peptides are unapproved and prohibited in sport ^[8]. The one directly relevant dose-response experiment in this corpus found that more was not better ^[9]. And the human tolerability data most often cited in support of the blend describe a different molecule from the one in the vial ^[11].

The BPC-157 page and the TB-500 page cover each half on its own evidence, and the comparison page lines all three up on the time axis together.